Roche outlined plans to become a 'top three' player in the obesity treatment market by 2030, leveraging multiple pipeline assets including acquired candidates from Carmot Therapeutics and co-development agreements with Zealand Pharma. The pharma giant is advancing injectable dual GLP-1/GIP receptor agonists and oral GLP-1 medications with promising clinical results. Roche emphasizes leveraging synergies across its portfolio and global capabilities to carve out a strong obesity franchise positioning for sustained growth in the weight loss sector.